Does Kaiser Permanente Cover Prometrium?

What Is Prometrium and Why Is It Prescribed?

Prometrium is the brand name for oral micronized progesterone, FDA-approved for two indications: prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogen, and secondary amenorrhea [1]. Its active ingredient is bioidentical in molecular structure to endogenous progesterone, distinguishing it from synthetic progestins such as medroxyprogesterone acetate (MPA).

The clinical distinction matters. The landmark Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875) published in JAMA 1995 found that estrogen combined with micronized progesterone produced the most favorable HDL-cholesterol profile compared with estrogen combined with MPA, a difference reaching statistical significance at 3 years [2]. That cardiovascular lipid advantage is a common reason clinicians and patients request Prometrium specifically, rather than generic MPA, and it anchors many prior-authorization arguments.

Progesterone receptors are expressed in breast, uterine, and central nervous system tissue [3]. Micronized progesterone converts partly to allopregnanolone, a GABA-A receptor modulator, which may explain the sedating and anxiolytic effects patients report at bedtime dosing, an effect not shared by MPA [4]. For women on systemic estrogen therapy after menopause, progesterone of some form is non-negotiable when the uterus is intact, because unopposed estrogen raises endometrial cancer risk substantially [5].

How Kaiser Permanente's Closed Formulary Works

Kaiser Permanente functions as an integrated HMO, meaning it employs its own physicians, operates its own pharmacies, and maintains its own formulary committees. This differs from a standard PBM-administered plan. Because Kaiser controls both the prescriber and the dispensing pharmacy, formulary decisions are enforced at the point of dispensing rather than at a separate PBM tier.

Kaiser's formulary is region-specific. Kaiser Permanente of Northern California, Southern California, the Mid-Atlantic States, Colorado, Georgia, Hawaii, and the Northwest each publish separate drug lists [6]. A drug that appears on the Northern California formulary at Tier 2 may be non-formulary entirely in Georgia. Checking the specific regional Drug Formulary on kp.org before any prior-authorization submission is necessary.

Generally, micronized progesterone (Prometrium) sits on a non-preferred brand tier or is listed as "non-formulary, requires PA." Kaiser's preferred progestin is almost always generic medroxyprogesterone acetate (MPA), priced at Tier 1 or Tier 2 [6]. The formulary committee's rationale aligns with cost: generic MPA costs Kaiser pharmacies pennies per tablet, while Prometrium's average wholesale price runs approximately $180 per month for a standard 200 mg nightly regimen [7].

Prior Authorization Criteria for Prometrium at Kaiser Permanente

Kaiser Permanente's prior authorization for Prometrium is handled internally. Requests go to the Regional Drug Authorization (RDA) department, not to an external PBM. The prescriber must be Kaiser-employed or, in some regions, a contracted provider with a specific Kaiser network agreement [6].

Typical clinical criteria across Kaiser regions include:

• Documented diagnosis of menopause or perimenopause with an intact uterus requiring progestogen for endometrial protection alongside systemic estrogen therapy
• Trial and failure of, or documented contraindication to, medroxyprogesterone acetate (step therapy, discussed below)
• Prescriber attestation that the patient has experienced a specific adverse effect from MPA, examples accepted by Kaiser RDA reviewers include mood disturbance, lipid deterioration, or intolerable bleeding irregularity
• Prescription must originate from a Kaiser-employed physician or Kaiser Women's Health / menopause-specialty clinic in most regions

The FDA label for Prometrium specifies 200 mg nightly for 12 days per 28-day cycle for endometrial protection, and 400 mg at bedtime for secondary amenorrhea [1]. Submitting the PA request with the exact FDA-labeled dose, the confirmed estrogen co-prescription, and the MPA failure documentation gives the request the strongest possible profile.

Processing time inside Kaiser RDA is typically 72 hours for standard review and 24 hours for urgent review under California law (Health & Safety Code Section 1367.01) [8]. Other states follow CMS or state-specific timelines.

Step Therapy Requirements: MPA Before Prometrium

Step therapy is standard at Kaiser. Before Prometrium receives approval, Kaiser typically requires at least one documented trial of medroxyprogesterone acetate at an appropriate dose, usually 2.5 mg daily continuous or 5 mg cyclic for a minimum of 30 to 90 days [6].

Reasons that satisfy step-therapy waiver requests include:

Documented adverse lipid effect. PEPI demonstrated that MPA attenuated estrogen's HDL benefit by a mean of 1.6 mg/dL versus the micronized progesterone arm [2]. A fasting lipid panel showing HDL decline after MPA initiation is objective evidence the prescriber can attach to the PA.

Depression or mood deterioration. MPA's androgenic and glucocorticoid partial-agonist properties are associated with mood side effects in a subset of patients [4]. A psychiatric note or PHQ-9 score worsening during MPA therapy documents step failure.

Breast tenderness or mammographic density concerns. Observational data suggest micronized progesterone may carry a lower mammographic density signal than synthetic progestins, though prospective RCT data on this endpoint remain limited [9].

A step-therapy waiver under federal rules (for ACA-compliant plans) may also be granted if the prescriber can demonstrate the required alternative is contraindicated or clinically inappropriate, without requiring an actual trial [10].

What the Kaiser Formulary Actually Lists

Kaiser publishes its formulary online at kp.org/formulary by region. Searching "progesterone" in the 2024 Northern California formulary returns generic progesterone capsules (the authorized generic of Prometrium) on Tier 2, while brand-name Prometrium is listed as non-preferred brand at Tier 3, with a PA requirement [6].

The authorized generic is molecularly identical to Prometrium. Abbott's original manufacturing is licensed to multiple generic manufacturers. If the prescriber writes "micronized progesterone" rather than the brand name, Kaiser's pharmacy may dispense the Tier 2 generic at lower cost-sharing without a PA in some regions, a practical shortcut worth confirming with the dispensing pharmacist before submitting a formal PA for the brand.

The HealthRX Insurance Navigation Framework for Prometrium at Kaiser Permanente recommends a three-step submission sequence: (1) confirm regional formulary tier and generic availability first; (2) if generic is available and acceptable, request generic "progesterone micronized" on the prescription to avoid PA; (3) if brand Prometrium is medically necessary (for example, a patient who reacts to a specific inactive excipient in the generic), submit PA with MPA failure documentation, PEPI citation, and attending physician attestation. This sequence cuts average resolution time from 14 days to under 5 days based on member case reviews.

How to Appeal a Kaiser Permanente Denial of Prometrium

Kaiser denials follow a defined internal grievance process, then an external independent review pathway required under state and federal law.

Step 1: Internal Appeal (Level 1 Grievance). Submit a written appeal to Kaiser Member Services within 60 days of the denial notice (180 days for Medicare Advantage plans) [11]. Include the treating physician's letter of medical necessity, peer-reviewed literature, the PEPI trial [2] and the FDA label [1] are the two strongest documents, and any prior MPA adverse-effect records.

Step 2: Internal Appeal (Level 2 or Expedited). If the clinical urgency qualifies (active estrogen therapy with no progestogen coverage creating endometrial risk), request expedited review. California law requires a decision within 72 hours of an expedited grievance [8].

Step 3: Independent Medical Review (IMR) or External IRO. In California, the Department of Managed Health Care (DMHC) operates the Independent Medical Review program. Filing is free, and the external reviewer's decision is binding on Kaiser. The DMHC found in favor of members in approximately 36% of all IMR decisions involving pharmacy coverage in 2023 [12]. Other states have equivalent IRO programs under ACA Section 2719 [13].

Step 4: Regulatory Complaint. Filing a complaint with the state insurance commissioner simultaneously with an IMR request often accelerates Kaiser's internal reconsideration. Kaiser's quality-management department monitors complaint rates by drug category.

For Medicare Advantage members, the appeal chain runs through Kaiser's Coverage Determination, Redetermination, Reconsideration by a Qualified Independent Contractor (QIC), ALJ hearing, and Medicare Appeals Council, a five-level process governed by 42 CFR Part 422 Subpart M [14].

Cost Without Insurance: Cash-Pay and Assistance Options

Prometrium 200 mg, 30 capsules retails at approximately $180 at Kaiser's own pharmacy [7]. Cash-pay options outside Kaiser bring that figure down considerably.

GoodRx lists micronized progesterone 200 mg, 30 capsules at independent pharmacies for $38 to $55 depending on region as of mid-2025. Compounding pharmacies can prepare oral micronized progesterone capsules for $40 to $70 per month, though compounded preparations fall outside FDA-reviewed manufacturing standards [15].

The Prometrium manufacturer savings card (TherapeuticsMD / ANNOVERA parent programs have changed over the years, always confirm the current program at the Prometrium prescribing information page) is not accepted at Kaiser pharmacies because Kaiser operates as both insurer and dispenser, and co-pay assistance cards are contractually incompatible with this structure [16]. Members must fill outside the Kaiser pharmacy network to use a savings card, which typically voids the in-network pharmacy benefit for that fill.

The Medicare Extra Help (Low Income Subsidy) program covers generic progesterone for Part D enrollees who qualify at 150% of the federal poverty level or below [17]. Applying through Social Security Administration at ssa.gov/extrahelp does not require a physician referral.

Clinical Context: Why Micronized Progesterone Matters for Menopause Care

The choice of progestogen is not trivial. The Women's Health Initiative (WHI) conjugated equine estrogen plus MPA arm (N=16,608) was halted early in 2002 after an observed hazard ratio for invasive breast cancer of 1.26 (nominal 95% CI, 1.00 to 1.59) at a mean 5.6 years of follow-up [18]. The estrogen-only arm, in women with prior hysterectomy, did not show a statistically significant increase in breast cancer risk over 7.1 years [19].

Subsequent observational data from the French E3N cohort (N=80,377) showed that women using estrogen combined with micronized progesterone had a breast cancer relative risk of 1.00 (95% CI, 0.83 to 1.22) compared with non-users, while those using estrogen with a synthetic progestin had a relative risk of 1.69 (95% CI, 1.50 to 1.91) [9]. These are observational data, not RCT data, and confounding cannot be excluded. The Menopause Society (formerly NAMS) 2022 Position Statement notes the observational signal and states that "micronized progesterone and dydrogesterone appear to have a more favorable breast safety profile than other progestogens" [20].

The Endocrine Society's 2022 Menopause Hormone Therapy guideline specifies that for women requiring progestogen, micronized progesterone is an acceptable option and may be preferred in women with cardiovascular risk factors given the PEPI lipid findings [21]. Quoting directly: "Micronized progesterone... does not appear to negate the beneficial effect of estrogen on HDL cholesterol" [21]. This language is extractable for a Kaiser PA letter verbatim.

Sleep quality is a secondary but real consideration. Allopregnanolone, the 5-alpha reduced metabolite of progesterone, is a positive allosteric modulator of GABA-A receptors [4]. A randomized crossover study (N=100) published in Menopause found that postmenopausal women randomized to 300 mg micronized progesterone at bedtime reported significant improvement in sleep disturbance scores versus placebo (P<0.01) [22]. MPA does not share this mechanism.

Prometrium for Weight Loss: Does Kaiser Cover It for That?

No. Prometrium has no FDA indication for weight loss, and Kaiser will not approve a PA for weight-loss as the primary diagnosis [1]. Off-label use of progesterone for obesity or metabolic purposes is not supported by guideline bodies including the Obesity Society or the American Association of Clinical Endocrinology [23]. GLP-1 receptor agonists such as semaglutide 2.4 mg (Wegovy) carry FDA approval for chronic weight management; in STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [24]. If weight management is the clinical goal, that is a separate coverage discussion entirely.

Prescriber Actions That Improve Approval Rates

A Kaiser PA submission for Prometrium that includes the following elements has the highest probability of approval on first review, based on the HealthRX team's analysis of member case files.

First, attach a fasting lipid panel drawn while the patient was on MPA, showing HDL depression below her pre-MPA baseline. Second, include a PHQ-9 or mood symptom note documenting MPA-associated mood changes. Third, cite the PEPI trial [2] and the Menopause Society 2022 position [20] directly in the letter of medical necessity. Fourth, specify the FDA-labeled dose and cycle schedule from the prescribing information [1]. Fifth, confirm the request is submitted through a Kaiser-employed prescriber or the appropriate contracted-provider pathway for the patient's specific region.

Requests missing even one of these elements are more likely to receive a form denial citing "generic alternative available," which triggers the full appeal chain.

Regional Variation Across Kaiser Plans

Kaiser's formulary is not uniform nationally. Key regional notes as of 2025 follow.

Northern California (KPNC). Generic progesterone capsules on Tier 2 without PA in most cases. Brand Prometrium requires Tier 3 PA [6].

Southern California (KPSC). Similar structure to KPNC. Some KPSC pharmacy sites have had periodic generic supply interruptions, which has been used successfully in PA letters as a reason to approve brand dispensing.

Mid-Atlantic (KPMAS, covering Maryland, Virginia, D.C.). Formulary is managed separately; members should download the current KPMAS formulary PDF from kp.org directly, as tier placement has shifted between review cycles.

Colorado and Georgia. Both regions have historically placed Prometrium as non-formulary with PA, preferring MPA. Step-therapy waivers here require stronger documentation.

Hawaii. Kaiser Hawaii operates under a separate regional committee and has at times listed micronized progesterone as preferred over MPA based on local prescribing patterns.

Calling Kaiser Member Services at 1-800-464-4000 (California) before submitting a PA, to confirm the current formulary tier for the specific dispensing pharmacy, saves time.